AHA yesterday sent a letter to the Department of Justice’s Antitrust Division expressing its serious concern with the adequacy of any remedy to resolve the anticompetitive impact of UnitedHealth Group’s acquisition of Change Healthcare. UHG in January announced its intent to combine its Optum health services subsidiary with Change Healthcare, a health care technology firm, to provide software and data analytics, technology-enabled services and research, advisory and revenue cycle management services.

At the time, AHA argued that the deal would distort “decisions about patient care and claims processing and denials to the detriment of consumers and health care providers and further increase UHG’s already massive market power.” In the newest letter AHA reiterated that “it is highly unlikely that any remedy will preserve the substantial level of competition between the parties that will be lost if the transaction is completed.”

Related News Articles

Headline
AHA, joined by the Association of American Medical Colleges, this week filed an amicus brief in response to the Federal Trade Commission’s challenge to a…
Headline
The AHA today urged the Health Resources and Services Administration to quickly distribute the $17 billion in Phase 4 provider relief funds and $8.5 billion in…
Headline
The AHA today released the latest edition of the COVID-19 Snapshot, underscoring the persisting challenges facing hospitals and health systems during the…
Headline
The House last night voted 220-211 to pass a continuing resolution that would generally extend current federal funding levels for health care and all…
Headline
In a study reported this week in JAMA Network Open, rural hospital mergers were associated with lower mortality for patients admitted to the hospital for…
Headline
The House today is expected to consider a continuing resolution that would generally extend current federal funding levels for health care and all other…